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AbstrAct
Objective
To review and critically appraise published and 
preprint reports of prediction models for diagnosing 
coronavirus disease 2019 (covid-19) in patients with 
suspected infection, for prognosis of patients with 
covid-19, and for detecting people in the general 
population at risk of being admitted to hospital for 
covid-19 pneumonia.
Design
Rapid systematic review and critical appraisal.
Data sOurces
PubMed and Embase through Ovid, Arxiv, medRxiv, 
and bioRxiv up to 24 March 2020.
stuDy selectiOn
Studies that developed or validated a multivariable 
covid-19 related prediction model.
Data extractiOn
At least two authors independently extracted data 
using the CHARMS (critical appraisal and data 
extraction for systematic reviews of prediction 
modelling studies) checklist; risk of bias was 
assessed using PROBAST (prediction model risk of 
bias assessment tool).
results
2696 titles were screened, and 27 studies describing 
31 prediction models were included. Three models 
were identified for predicting hospital admission from 
pneumonia and other events (as proxy outcomes for 
covid-19 pneumonia) in the general population; 18 
diagnostic models for detecting covid-19 infection 
(13 were machine learning based on computed 
tomography scans); and 10 prognostic models for 
predicting mortality risk, progression to severe 
disease, or length of hospital stay. Only one study 
used patient data from outside of China. The most 
reported predictors of presence of covid-19 in 
patients with suspected disease included age, body 
temperature, and signs and symptoms. The most 
reported predictors of severe prognosis in patients 
with covid-19 included age, sex, features derived 
from computed tomography scans, C reactive protein, 
lactic dehydrogenase, and lymphocyte count. C index 
estimates ranged from 0.73 to 0.81 in prediction 
models for the general population (reported for 
all three models), from 0.81 to more than 0.99 in 
diagnostic models (reported for 13 of the 18 models), 
and from 0.85 to 0.98 in prognostic models (reported 
for six of the 10 models). All studies were rated at high 
risk of bias, mostly because of non-representative 
selection of control patients, exclusion of patients 
who had not experienced the event of interest by the 
end of the study, and high risk of model overfitting. 
Reporting quality varied substantially between 
studies. Most reports did not include a description of 
the study population or intended use of the models, 
and calibration of predictions was rarely assessed.
cOnclusiOn
Prediction models for covid-19 are quickly entering 
the academic literature to support medical decision 
making at a time when they are urgently needed. This 
review indicates that proposed models are poorly 
reported, at high risk of bias, and their reported 
performance is probably optimistic. Immediate 
sharing of well documented individual participant 
data from covid-19 studies is needed for collaborative 
efforts to develop more rigorous prediction models 
and validate existing ones. The predictors identified 
in included studies could be considered as candidate 
predictors for new models. Methodological guidance 
should be followed because unreliable predictions 
could cause more harm than benefit in guiding 
clinical decisions. Finally, studies should adhere to 
the TRIPOD (transparent reporting of a multivariable 
prediction model for individual prognosis or 
diagnosis) reporting guideline.
systematic review registratiOn
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WhAt is AlreAdy knoWn on this topic
The sharp recent increase in coronavirus disease 2019 (covid-19) infections 
has put a strain on healthcare systems worldwide; there is an urgent need 
for efficient early detection, diagnosis of covid-19 in patients with suspected 
disease, and prognosis of covid-19 in patients with confirmed disease
Viral nucleic acid testing and chest computed tomography (CT) are standard 
methods for diagnosing covid-19, but are time consuming
Earlier reports suggest that elderly patients, patients with comorbidities (chronic 
obstructive pulmonary disease, cardiovascular disease, hypertension), and 
patients presenting with dyspnoea are vulnerable to more severe morbidity and 
mortality after covid-19 infection
WhAt this study Adds
Three models were identified that predict hospital admission from pneumonia 
and other events (as proxy outcomes for covid-19 pneumonia) in the general 
population
Eighteen diagnostic models were identified for detecting covid-19 infection 
(13 were machine learning based on CT scans); and 10 prognostic models for 
predicting mortality risk, progression to severe disease, or length of hospital stay
Proposed models are poorly reported and at high risk of bias, raising concern 
that their predictions could be unreliable when applied in daily practice
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introduction
The novel coronavirus disease 2019 (covid-19) presents 
an important and urgent threat to global health. Since 
the outbreak in early December 2019 in the Hubei 
province of the People’s Republic of China, the number 
of patients confirmed to have the disease has exceeded 
775 000 in more than 160 countries, and the number 
of people infected is probably much higher. More than 
36 000 people have died from covid-19 infection (up 
to 30 March 2020).1 Despite public health responses 
aimed at containing the disease and delaying the 
spread, several countries have been confronted with 
a critical care crisis, and more countries will almost 
certainly follow.2-4 Outbreaks lead to important 
increases in the demand for hospital beds and shortage 
of medical equipment, while medical staff themselves 
could also get infected.
To mitigate the burden on the healthcare system, 
while also providing the best possible care for 
patients, efficient diagnosis and prognosis of the 
disease is needed. Prediction models that combine 
several variables or features to estimate the risk of 
people being infected or experiencing a poor outcome 
from the infection could assist medical staff in 
triaging patients when allocating limited healthcare 
resources. Models ranging from rule based scoring 
systems to advanced machine learning models (deep 
learning) have been proposed and published in 
response to a call to share relevant covid-19 research 
findings rapidly and openly to inform the public 
health response and help save lives.5 Many of these 
prediction models are published in open access 
repositories, ahead of peer review.
We aimed to systematically review and critically 
appraise currently available prediction models for 
covid-19, in particular diagnostic and prognostic 
models for the disease. This systematic review was 
carried out in collaboration with the Cochrane 
Prognosis Methods Group.
Methods
We searched PubMed and Embase through Ovid, 
bioRxiv, medRxiv, and arXiv for research on covid-19 
published after 3 January 2020. We used the publicly 
available publication list of the covid-19 living 
systematic review.6 This list contains studies on 
covid-19 published on PubMed and Embase through 
Ovid, bioRxiv, and medRxiv, and is continuously 
updated. We validated the list to examine whether it 
is fit for purpose by comparing it to relevant hits from 
bioRxiv and medRxiv when combining covid-19 search 
terms (covid-19, sars-cov-2, novel corona, 2019-
ncov) with methodological search terms (diagnostic, 
prognostic, prediction model, machine learning, 
artificial intelligence, algorithm, score, deep learning, 
regression). All relevant hits were found on the living 
systematic review list.6 We supplemented this list with 
hits from PubMed by searching for “covid-19” because 
when we performed our intitial search this term was 
not included in the reported living systematic review6 
search terms for PubMed. We further supplemented 
the list with studies on covid-19 retrieved from arXiv. 
The online supplementary material presents the 
search strings. Additionally, we contacted authors for 
studies that were not publicly available at the time of 
the search,7 8 and included studies that were publicly 
available but not on the living systematic review6 list at 
the time of our search.9-12
We initially searched databases on 13 March 2020, 
with an update on 24 March 2020. All studies were 
considered, regardless of language or publication 
status (preprint or peer reviewed articles). We included 
studies if they developed or validated a multivariable 
model or scoring system, based on individual 
participant level data, to predict any covid-19 related 
outcome. These models included diagnostic and 
prognostic models for covid-19, or those aiming 
to identify people at increased risk of developing 
covid-19 pneumonia in the general population. No 
restrictions were made on the setting (eg, inpatients, 
outpatients, or general population), prediction 
horizon (how far ahead the model predicts), included 
predictors, or outcomes. Epidemiological studies 
that aimed to model disease transmission or fatality 
rates, diagnostic test accuracy, and predictor finding 
studies were excluded. Titles, abstracts, and full texts 
were screened in duplicate for eligibility by pairs of 
independent reviewers (from LW, BVC, and MvS), and 
discrepancies were resolved through discussion.
Data extraction of included articles was done by 
two independent reviewers (from LW, BVC, GSC, TPAD, 
MCH, GH, KGMM, RDR, ES, LJMS, EWS, KIES, CW, and 
MvS). Reviewers used a standardised data extraction 
form based on the CHARMS (critical appraisal and 
data extraction for systematic reviews of prediction 
modelling studies) checklist13 and PROBAST (predic-
tion model risk of bias assessment tool).14 We sought 
to extract each model’s predictive performance by 
using whatever measures were presented. These 
measures included any summaries of discrimination 
(the extent to which predicted risks discriminate 
between participants with and without the outcome), 
and calibration (the extent to which predicted risks 
correspond to observed risks) as recommended in 
the TRIPOD (transparent reporting of a multivariable 
prediction model for individual prognosis or diagnosis) 
statement.15 Discrimination is often quantified by the C 
index (C index=1 if the model discriminates perfectly; 
C index=0.5 if discrimination is no better than chance). 
Calibration is often quantified by the calibration 
intercept (which is zero when the risks are not 
systematically overestimated or underestimated) and 
calibration slope (which is one if the predicted risks 
are not too extreme or too moderate).16 We focus on 
performance statistics as estimated from the strongest 
available form of validation. Any discrepancies in 
data extraction were resolved by LW and MvS. The 
online supplementary material provides details on 
data extraction. We considered aspects of PRISMA 
(preferred reporting items for systematic reviews 
and meta-analyses)17 and TRIPOD15 in reporting our 
article. 
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Patient and public involvement
It was not appropriate or possible to involve patients or 
the public in the design, conduct, or reporting of our 
research. The study protocol and preliminary results 
are publicly available on https://osf.io/ehc47/ and 
medRxiv.
results
We retrieved 2690 titles through our systematic 
search (fig 1; 1916 on 13 March 2020 and 774 
during an update on 24 March 2020). Two additional 
unpublished studies were made available on request 
(after a call on social media). We included a further 
four studies that were publicly available but were not 
detected by our search. Of 2696 titles, 85 studies were 
retained for abstract and full text screening. Twenty 
seven studies describing 31 prediction models met the 
inclusion criteria and were selected for data extraction 
and critical appraisal.7-12 18-38
Primary da tasets
Twenty five studies used data on patients with 
covid-19 from China (supplementary table 1), one 
study used data on patients from Italy,31 and one 
study used international data (United States, United 
Kingdom, and China, among others).35 Based on 18 
of the 25 studies that reported study dates, data were 
collected between 8 December 2019 and 15 March 
2020. The duration of follow-up was unclear in most 
studies, although one reported a median follow-up of 
8.4 days,19 while another reported a median follow-up 
of 15 days.37 Some Chinese centres provided data to 
multiple studies, but it was unclear how much these 
datasets overlapped across our 25 identified studies. 
One study used US Medicare claims data from 2015 
to 2016 to estimate vulnerability to covid-19,8 two 
studies used control CT (computed tomography) 
scans from the US or Switzerland,11 25 and one study 
used simulated data.18All but one study24 developed 
prediction models for use in adults. The median age 
varied between studies (from 34 to 65 years; see 
supplementary table 1), as did the proportion of men 
(from 41% to 61%).
Among the six studies that developed prognostic 
models to predict mortality risk in people with 
confirmed or suspected covid-19 infection, the 
percentage of deaths varied between 8% and 59% 
(table 1). This wide variation is partly because of 
severe sampling bias caused by studies excluding 
participants who still had the disease at the end of the 
study period (that is, they had neither recovered nor 
died).7 20-22 Additionally, length of follow-up could 
have varied between studies (but was rarely reported), 
and there might be local and temporal variation in how 
people were diagnosed as having covid-19 or were 
admitted to the hospital (and therefore recruited for 
the studies). Among the 18 diagnostic model studies, 
only one reported on prevalence of covid-19 infection 
in people with suspected covid-19; the prevalence 
was 19% (development dataset) and 24% (validation 
dataset).30 One study reported that 8% of patients had 
severe disease among confirmed paediatric patients 
with covid-19 infection.24 Because 16 diagnostic 
studies used either case-control sampling or an unclear 
method of data collection, the prevalence in these 
diagnostic studies might not have been representative 
of their target population.
Table 1 gives an overview of the 31 prediction models 
reported in the 27 identified studies. Supplementary 
table 2 provides modelling details and box 1 discusses 
the availability of models in a format for use in clinical 
practice.
models to predict risk of hospital admission for 
covid-19 pneumonia in general population
We identified three models that predicted risk of 
hospital admission for covid-19 pneumonia in the 
general population, but used admission for non-
tuberculosis pneumonia, influenza, acute bronchitis, 
or upper respiratory tract infections as outcomes in a 
dataset without any patients with covid-19 (table 1).8 
Among the predictors were age, sex, previous hospital 
admissions, comorbidity data, and social determinants 
of health. The study estimated C indices of 0.73, 0.81, 
and 0.81 for the three models.
Diagnostic models to detect covid-19 infection in 
patients with symptoms
We identified one study that developed a model to detect 
covid-19 pneumonia in fever clinic patients (estimated 
C index 0.94)10; one to diagnose covid-19 in patients 
with suspected disease (estimated C index 0.97)30; 
one to diagnose covid-19 in patients with suspected 
disease and asymptomatic patients (estimated C index 
0.87)12; and one to diagnose covid-19 by using deep 
learning of genomic sequences (estimated C index 
0.98).35 A further study was developed to diagnose 
severe disease in paediatric inpatients with symptoms, 
based on direct bilirubin and alanine transaminase 
(reporting an F1 score of 1.00, indicating 100% 
observed sensitivity and specificity).24 Only one study 
reported assessing calibration, but it was unclear 
how this was done.12 Predictors used in more than 
one model were age (n=3), body temperature or fever 
(n=2), and signs and symptoms (such as shortness 
of breath, headache, shiver, sore throat, and fatigue, 
n=2; table 1).
Thirteen prediction models were proposed to support 
the diagnosis of covid-19 or covid-19 pneumonia 
(and monitor progression) based on CT images. The 
predictive performance varied widely, with estimated 
C index values ranging from 0.81 to nearly 1.
Prognostic models for patients with a diagnosis of 
covid-19 infection
We identified 10 prognostic models (table 1). Of these, 
six estimated mortality risk in patients with suspected 
or confirmed covid-19.7 18 19 21 22 37 The intended use 
of these models (that is, when to use them, in whom 
to use them, and the prediction horizon, eg, mortality 
by what time) was not clearly described. Two models 
aimed to predict a hospital stay of more than 10 days 
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from admission.20 Two models aimed to predict 
progression to a severe or critical state.9 32 Predictors 
included in more than one prognostic model were age 
(n=5), sex (n=2), features derived from CT scoring 
(n=5), C reactive protein (n=3), lactic dehydrogenase 
(n=3), and lymphocyte count (n=2; table 1).
Only two studies that predicted mortality reported 
a C index; these studies obtained estimates of 0.9022 
and 0.98.7 One study also evaluated calibration.7 
When applied to new patients, their model yielded 
probabilities of mortality that were too high for low risk 
patients and too low for high risk patients (calibration 
slope >1), despite excellent discrimination.7 One 
study developed two models to predict a hospital 
stay of more than 10 days and estimated C indices 
of 0.92 and 0.96.20 The two studies that developed 
models to predict progression to a severe or critical 
state estimated C indices of 0.95 and 0.85.9 32 One of 
these studies also reported perfect calibration, but it 
was unclear how this was evaluated.32
risk of bias
All models were at high risk of bias according to 
assessment with PROBAST (table 1), which suggests 
that their predictive performance when used in 
practice is probably lower than that reported. There-
fore, there is cause for concern that the predictions 
of these models are unreliable. Box 2 gives details on 
common causes for risk of bias for each type of model.
Eleven of the 27 studies had a high risk of bias for 
the participants domain (table 2), which indicates 
that the participants enrolled in the studies might not 
be representative of the models’ targeted populations. 
Unclear reporting on the inclusion of participants 
prohibited a risk of bias assessment in eight studies. 
Four of the 27 studies had a high risk of bias for the 
predictors domain, which indicates that predictors 
were not available at the models’ intended time 
of use, not clearly defined, or influenced by the 
outcome measurement. The diagnostic model studies 
that used CT imaging predictors were all scored as 
unclear on the predictors domain. The publications 
often lacked clear information on the preprocessing 
steps (eg, cropping of images). Moreover, complex 
machine learning algorithms transform CT images 
into predictors in an untransparent way, which makes 
it challenging to fully apply the PROBAST predictors 
section for such imaging studies. Most studies used 
outcomes that are easy to assess (eg, death, presence 
of covid-19 by laboratory confirmation). Nonetheless, 
there was reason to be concerned about bias 
induced by the outcome measurement in 10 studies 
Additional records identified through other sources
Articles excluded
Not a prediction model development or
  validation study
Epidemiological model to estimate
  disease transmission or case fatality rate
Commentary, editorial or letter
Methods paper
Duplicate article
26
12
11
5
4
Records screened
Records identified through database searching
Records excluded
Articles assessed for eligibility
Studies included in review
85
58
27
2690
2696
2611
Models to identify people at
risk in the general population
Diagnostic models
(13 CT imaging studies)
Prognostic models
(6 for mortality, 2 models for
progression to severe or critical
state, 2 for length of stay)
6
18 103
Fig 1 | Prisma (preferred reporting items for systematic reviews and meta-analyses) flowchart of study inclusions 
and exclusions. ct=computed tomography
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because of the use of subjective or proxy outcomes (eg, 
non covid-19 severe respiratory infections).
All studies were at high risk of bias for the analysis 
domain (table 2). Many studies had small sample sizes 
(table 1), which led to an increased risk of overfitting, 
particularly if complex modelling strategies were used. 
Three studies did not report the predictive performance 
of the developed model, and one study reported 
only the apparent performance (the performance 
in exactly the same data used to develop the model, 
without adjustment for optimism owing to potential 
overfitting).
Four models were externally validated in the model 
development study (in an independent dataset, 
excluding random training test splits and temporal 
splits).7 12 25 32 However, in three of these studies, 
the external validation datasets are probably not 
representative of the target population (box 2).7 12 25 
Consequently, predictive performance could differ 
if the models were applied in the target population. 
Gong and colleagues had a satisfactory predictive 
performance on two unbiased but small external 
validation datasets.32 One study was a small (n=27) 
external validation that reported satisfactory predictive 
performance of a model originally developed for avian 
influenza H7N9 pneumonia. However, patients who 
had not recovered at the end of the study period were 
excluded, which led to selection bias.22 Only three 
studies assessed calibration,7 12 32 but the method 
to check calibration was probably suboptimal in two 
studies.12 32
discussion
In this systematic review of prediction models 
related to the covid-19 pandemic, we identified and 
critically appraised 27 studies that described 31 
models. These prediction models were developed for 
detecting people in the general population at risk of 
being admitted to hospital for covid-19 pneumonia, 
for diagnosis of covid-19 in patients with symptoms, 
and for prognosis of patients with covid-19 infection. 
All models reported good to excellent predictive 
performance, but all were appraised to have high risk 
of bias owing to a combination of poor reporting and 
poor methodological conduct for participant selection, 
predictor description, and statistical methods used. As 
expected, in these early covid-19 related prediction 
model studies, clinical data from patients with 
covid-19 are still scarce and limited to data from China, 
Italy, and international registries. With few exceptions, 
the available sample sizes and number of events for 
the outcomes of interest were limited. This is a well 
known problem when building prediction models and 
increases the risk of overfitting the model.44 A high risk 
of bias implies that these models will probably perform 
worse in practice than the performance reported by the 
researchers. Therefore, the estimated C indices, often 
close to 1 and indicating near perfect discrimination, 
are probably optimistic. Five studies carried out an 
external validation,7 12 22 25 32 and only one study 
assessed calibration correctly.7
We reviewed 13 studies that used advanced machine 
learning methodology on chest CT scans to diagnose 
covid-19 disease, covid-19 related pneumonia, or to 
assist in segmentation of lung images. The predictive 
performance measures showed a high to almost perfect 
ability to identify covid-19, although these models and 
their evaluations also had a high risk of bias, notably 
because of poor reporting and an artificial mix of 
patients with and without covid-19.
challenges and opportunities
The main aim of prediction models is to support medical 
decision making. Therefore it is vital to identify a target 
population in which predictions serve a clinical need, 
and a representative dataset (preferably comprising 
consecutive patients) on which the prediction 
model can be developed and validated. This target 
population must also be carefully described so that 
the performance of the developed or validated model 
can be appraised in context, and users know which 
people the model applies to when making predictions. 
However, the included studies in our systematic review 
often lacked an adequate description of the study 
population, which leaves users of these models in 
doubt about the models’ applicability. Although we 
recognise that all studies were done under severe time 
constraints caused by urgency, we recommend that 
any studies currently in preprint and all future studies 
box 1: availability of models in format for use in clinical practice
Twelve studies presented their models in a format for use in clinical practice. However, 
because all models were at high risk of bias, we do not recommend their routine use 
before they are properly externally validated.
models to predict risk of hospital admission for coronavirus disease 2019 (covid-19) 
pneumonia in general population
The “COVID-19 Vulnerability Index” to detect hospital admission for covid-19 
pneumonia from other respiratory infections (eg, pneumonia, influenza) is available as 
an online tool.8 39
Diagnostic models
The “COVID-19 diagnosis aid APP” is available on iOS and android devices to 
diagnose covid-19 in asymptomatic patients and those with suspected disease.12 
The “suspected COVID-19 pneumonia Diagnosis Aid System” is available as an online 
tool.10 40 The “COVID-19 early warning score” to detect covid-19 infection in adults is 
available as a score chart in an article.30 A decision tree to detect severe disease for 
paediatric patients with confirmed covid-19 is also available in an article.24
Diagnostic models based on computed tomography (ct) imaging
Three of the seven artificial intelligence models to assist with diagnosis based on CT 
images are available through web applications.23 26 29 41-43 One model is deployed in 16 
hospitals, but the authors do not provide any usable tools in their study.33
Prognostic models
To assist in the prognosis of mortality, a nomogram (a graphical aid to calculate 
mortality risk),7 a decision tree,21 and a CT based scoring rule are available in the 
articles.22 Additionally a nomogram exists to predict progression to severe covid-19 
disease.32
Five studies made their source code available on GitHub.8 11 34 35 38 Ten studies did 
not include any usable equation, format, or reference for use or validation of their 
prediction model.
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should adhere to the TRIPOD reporting guideline15 to 
improve the description of their study population and 
their modelling choices. TRIPOD translations (eg, in 
Chinese and Japanese) are also available at https://
www.tripod-statement.org.
A better description of the study population could 
also help us understand the observed variability in the 
reported outcomes across studies, such as covid-19 
related mortality. The variability in the relative 
frequencies of the predicted outcomes presents an 
important challenge to the prediction modeller. A 
prediction model applied in a setting with a different 
relative frequency of the outcome might produce 
predictions that are miscalibrated45 and might need to 
be updated before it can safely be applied in that new 
setting.16 46 Such an update might often be required 
when prediction models are transported to different 
healthcare systems, which requires data from patients 
with covid-19 to be available from that system.
Covid-19 prediction problems will often not present 
as a simple binary classification task. Complexities 
in the data should be handled appropriately. For 
example, a prediction horizon should be specified for 
prognostic outcomes (eg, 30 day mortality). If study 
participants have neither recovered nor died within 
that time period, their data should not be excluded 
from analysis, which most reviewed studies have done. 
Instead, an appropriate time to event analysis should 
be considered to allow for administrative censoring.16 
Censoring for other reasons, for instance because of 
quick recovery and loss to follow-up of patients who 
are no longer at risk of death from covid-19, could 
necessitate analysis in a competing risk framework.47
Instead of developing and updating predictions in 
their local setting, individual participant data from 
multiple countries and healthcare systems might 
allow better understanding of the generalisability and 
implementation of prediction models across different 
settings and populations. This approach could greatly 
improve the applicability and robustness of prediction 
models in routine care.48-52
The evidence base for the development and 
validation of prediction models related to covid-19 will 
quickly increase over the coming months. Together 
with the increasing evidence from predictor finding 
studies53-59 and open peer review initiatives for 
covid-19 related publications,60 data registries61-65 are 
being set up. To maximise the new opportunities and 
to facilitate individual participant data meta-analyses, 
the World Health Organization has recently released a 
new data platform to encourage sharing of anonymised 
covid-19 clinical data.66 To leverage the full potential 
of these evolutions, international and interdisciplinary 
collaboration in terms of data acquisition and model 
building is crucial.
study limitations
With new publications on covid-19 related prediction 
models rapidly entering the medical literature, this 
systematic review cannot be viewed as an up to date list 
of all currently available covid-19 related prediction 
models. Also, 24 of the studies we reviewed were only 
available as preprints. These studies might improve 
after peer review, when they enter the official medical 
literature. We also found other prediction models that 
are currently being used in clinical practice but without 
scientific publications,67 and web risk calculators 
launched for use while the scientific manuscript is still 
under review (and unavailable on request).68 These 
unpublished models naturally fall outside the scope of 
this review of the literature.
implications for practice
All 31 reviewed prediction models were found to have 
a high risk of bias, and evidence from independent 
external validation of these models is currently lacking. 
However, the urgency of diagnostic and prognostic 
models to assist in quick and efficient triage of patients 
in the covid-19 pandemic might encourage clinicians 
to implement prediction models without sufficient 
documentation and validation. Although we cannot 
let perfect be the enemy of good, earlier studies have 
box 2: common causes of risk of bias in the 19 reported prediction models
models to predict hospital admission for coronavirus disease 2019 (covid-19) 
pneumonia in general population
These models were based on Medicare claims data, and used proxy outcomes to 
predict hospital admission for covid-19 pneumonia, in the absence of patients with 
covid-19.8
Diagnostic models
People without covid-19 (or a proportion of them) were excluded, altering the disease 
prevalence.30 Controls had viral pneumonia, which is not representative of the target 
population for a screening model.12 The test used to determine the outcome varied 
between participants,12 or one of the predictors (fever) was part of the outcome 
definition.10 Predictors were dichotomised, which led to a loss of information.24 30 36
Diagnostic models based on computed tomography (ct) imaging
Generally, studies did not clearly report which patients had CT scans during clinical 
routine, and it was unclear whether the selection of controls was made from the target 
population (that is, patients with suspected covid-19).11 23 29 33 36 Often studies did 
not clearly report how regions of interest were annotated. Images were sometimes 
annotated by only one scorer without quality control,25 27 the model output influenced 
annotation,28 or the “ground truth” that was used to build the model was a composite 
outcome based on the same CT images used to make the prediction, among other 
factors.38 Careful description of model specification and subsequent estimation 
were lacking, challenging the transparency and reproducibility of the models. Every 
study used a different deep learning architecture, some were established and others 
specifically designed, without benchmarking the used architecture against others.
Prognostic models
Study participants were often excluded because they did not develop the outcome 
at the end of the study period but were still in follow-up (that is, they were in hospital 
but had not recovered or died), yielding a highly selected study sample.7 20-22 
Additionally, only one study accounted for censoring by using Cox regression.19 
One study developed a model to predict future severity using cross sectional data 
(some participants were severely ill at inclusion)37; this implies that the timing of the 
measurement of the predictors is not appropriate and the (unclearly defined) outcome 
might have been influenced by the predictor values. Other studies used highly 
subjective predictors,22 or the last available predictor measurement from electronic 
health records (rather than measuring the predictor value at the time when the model 
was intended for use).21
 o
n
 20 April 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m1328 on 7 April 2020. Downloaded from 
RESEARCH
the bmj | BMJ 2020;369:m1328 | doi: 10.1136/bmj.m1328 9
shown that models were of limited use in the context 
of a pandemic,69 and they could even cause more harm 
than good.70 Therefore, we cannot recommend any 
model for use in practice at this point.
We anticipate that more covid-19 data at the 
individual participant level will soon become available. 
These data could be used to validate and update 
currently available prediction models.16 For example, 
one model that predicted progression to severe covid-19 
disease within 15 days of admission to hospital showed 
promising discrimination when validated externally 
on two small but unselected cohorts.32 Because 
reporting in this study was insufficiently detailed 
and the validation was in small Chinese datasets, 
validation in larger, international datasets is needed. 
Owing to differences between healthcare systems (eg, 
Chinese and European) on when patients are admitted 
to and discharged from hospital, and testing criteria 
for patients with covid-19, we anticipate most existing 
models will need to be updated (that is, adjusted to the 
local setting).
When building a new prediction model, we recom-
mend building on previous literature and expert 
opinion to select predictors, rather than selecting 
predictors in a purely data driven way16; this is 
especially true for datasets with limited sample size.71 
Based on the predictors included in multiple models 
identified by our review, we encourage researchers to 
consider incorporating several candidate predictors: 
for diagnostic models, these include age, body 
temperature, and (respiratory) signs and symptoms; for 
prognostic models, age, sex, C reactive protein, lactic 
dehydrogenase, lymphocyte count, and potentially 
features derived from CT scoring. Predictors that were 
included in both diagnostic and prognostic models 
were albumin (or albumin/globin), direct bilirubin, 
and red blood cell distribution width; these predictors 
could be considered as well. By pointing to the most 
important methodological challenges and issues in 
design and reporting of the currently available models, 
we hope to have provided a useful starting point for 
further studies aiming to develop new models, or to 
validate and update existing ones.
This systematic review aims to be the first stage of 
a living review of this field, in collaboration with the 
Cochrane Prognosis Methods Group. We will update 
this review and appraisal continuously, to provide up-
to-date information for healthcare decision makers 
and professionals as more international research 
emerges over time.
conclusion
Diagnostic and prognostic models for covid-19 are 
available and they all appear to show good to excellent 
discriminative performance. However, these models 
are at high risk of bias, mainly because of non-
representative selection of control patients, exclusion 
of patients who had not experienced the event of 
interest by the end of the study, and model overfitting. 
Therefore, their performance estimates are likely to 
be optimistic and misleading. Future studies should 
address these concerns. Sharing data and expertise 
for development, validation, and updating of covid-19 
related prediction models is urgently needed.
autHOr aFFiliatiOns
1Department of Epidemiology, CAPHRI Care and Public Health 
Research Institute, Maastricht University, Peter Debyeplein 1, 6229 
HA Maastricht, Netherlands
2Department of Development and Regeneration, KU Leuven, 
Leuven, Belgium
3Department of Biomedical Data Sciences, Leiden University 
Medical Centre, Leiden, Netherlands
4Julius Center for Health Sciences and Primary Care, University 
Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands
5Department of Medical Microbiology, University Medical Centre 
Utrecht, Utrecht, Netherlands
6Centre for Statistics in Medicine, Nuffield Department of 
Orthopaedics, Musculoskeletal Sciences, University of Oxford, 
Oxford, UK
7NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, 
Oxford, UK
8Cochrane Netherlands, University Medical Centre Utrecht, Utrecht 
University, Utrecht, Netherlands
9Department of Electrical Engineering, ESAT Stadius, KU Leuven, 
Leuven, Belgium
10Section for Clinical Biometrics, Centre for Medical Statistics, 
Informatics and Intelligent Systems, Medical University of Vienna, 
Vienna, Austria
11Ordensklinikum Linz, Hospital Elisabethinen, Department of 
Nephrology, Linz, Austria
table 2 | risk of bias assessment (using PrObast) based on four domains across 27 
studies that created prediction models for coronavirus disease 2019
authors
risk of bias
Participants Predictors Outcome analysis
Hospital admission in general population
DeCaprio et al8 High Low High High
Diagnosis
Feng et al10 Low Unclear High High
Lopez-Rincon et al35 Unclear Low Low High
Meng et al12 High Low High High
Song et al30 High Unclear Low High
Yu et al24 Unclear Unclear Unclear High
Diagnostic imaging
Barstugan et al31 Unclear Unclear Unclear High
Chen et al26 High Unclear Low High*
Gozes et al25 Unclear Unclear High High
Jin et al11 High Unclear Unclear High†
Jin et al33 High Unclear High High*
Li et al34 Low Unclear Low High
Shan et al28 Unclear Unclear High High†
Shi et al36 High Unclear Low High
Wang et al29 High Unclear Low High
Xu et al27 High Unclear High High
Song et al23 Unclear Unclear Low High
Zheng et al38 Unclear Unclear High High
Prognosis
Bai et al9 Low Unclear Unclear High
Caramelo et al18 High High High High
Gong et al32 Low Unclear Unclear High
Lu et al19 Low Low Low High
Qi et al20 Unclear Low Low High
Shi et al37 High High High High
Xie et al7 Low Low Low High
Yan et al21 Low High Low High
Yuan et al22 Low High Low High
PROBAST=prediction model risk of bias assessment tool.
*Risk of bias high owing to calibration not being evaluated. If this criterion is not taken into account, analysis risk 
of bias would have been unclear.
†Risk of bias high owing to calibration not being evaluated. If this criterion is not taken into account, analysis risk 
of bias would have been low.
 o
n
 20 April 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m1328 on 7 April 2020. Downloaded from 
RESEARCH
10 doi: 10.1136/bmj.m1328 | BMJ 2020;369:m1328 | the bmj
12Centre for Prognosis Research, School of Primary, Community and 
Social Care, Keele University, Keele, UK
13Charité Universitätsmedizin Berlin, corporate member of Freie 
Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
14Berlin Institute of Health, Berlin, Germany
We thank the authors who made their work available by posting it on 
public registries or sharing it confidentially.
Contributors: LW conceived the study. LW and MvS designed the 
study. LW, MvS, and BVC screened titles and abstracts for inclusion. 
LW, BVC, GSC, TPAD, MCH, GH, KGMM, RDR, ES, LJMS, EWS, KIES, CW, 
and MvS extracted and analysed data. MDV helped interpret the 
findings on deep learning studies and MMJB and MCH assisted in 
the interpretation from a clinical viewpoint. LW and MvS wrote the 
first draft, which all authors revised for critical content. All authors 
approved the final manuscript. LW and MvS are the guarantors. The 
corresponding author attests that all listed authors meet authorship 
criteria and that no others meeting the criteria have been omitted.
Funding: LW is a postdoctoral fellow of Research Foundation–
Flanders (FWO). BVC received support from FWO (grant G0B4716N) 
and Internal Funds KU Leuven (grant C24/15/037). TPAD 
acknowledges financial support from the Netherlands Organisation 
for Health Research and Development (grant No 91617050). 
KGMM gratefully acknowledges financial support from Cochrane 
Collaboration (SMF 2018). KIES is funded by the National Institute for 
Health Research School for Primary Care Research (NIHR SPCR). The 
views expressed are those of the author(s) and not necessarily those 
of the NHS, the NIHR, or the Department of Health and Social Care. 
GSC was supported by the NIHR Biomedical Research Centre, Oxford, 
and Cancer Research UK (programme grant C49297/A27294). The 
funders played no role in study design, data collection, data analysis, 
data interpretation, or reporting. The guarantors had full access to all 
the data in the study, take responsibility for the integrity of the data 
and the accuracy of the data analysis, and had final responsibility for 
the decision to submit for publication.
Competing interests: All authors have completed the ICMJE uniform 
disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no 
support from any organisation for the submitted work; no competing 
interests with regards to the submitted work; LW discloses support 
from Research Foundation–Flanders (FWO); RDR reports personal 
fees as a statistics editor for The BMJ (since 2009), consultancy fees 
for Roche for giving meta-analysis teaching and advice in October 
2018, and personal fees for delivering in-house training courses at 
Barts and The London School of Medicine and Dentistry, and also the 
Universities of Aberdeen, Exeter, and Leeds, all outside the submitted 
work.
Ethical approval: Not required.
Data sharing: The study protocol is available online at https://osf.
io/ehc47/. Most included studies are publically available. Additional 
data are available upon reasonable request.
The lead authors affirm that the manuscript is an honest, accurate, 
and transparent account of the study being reported; that no 
important aspects of the study have been omitted; and that any 
discrepancies from the study as planned have been explained.
Dissemination to participants and related patient and public 
communities: The study protocol is available online at https://osf.
io/ehc47/. A preprint version of the study is publicly available on 
medRxiv.
This is an Open Access article distributed in accordance with the 
terms of the Creative Commons Attribution (CC BY 4.0) license, which 
permits others to distribute, remix, adapt and build upon this work, 
for commercial use, provided the original work is properly cited. See: 
http://creativecommons.org/licenses/by/4.0/.
1  Dong E, Du H, Gardner L. An interactive web-based dashboard 
to track COVID-19 in real time. Lancet Infect Dis 2020:S1473-
3099(20)30120-1. doi:10.1016/S1473-3099(20)30120-1
2  Arabi YM, Murthy S, Webb S. COVID-19: a novel coronavirus and 
a novel challenge for critical care. Intensive Care Med 2020. 
doi:10.1007/s00134-020-05955-1 
3  Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the 
COVID-19 outbreak in Lombardy, Italy: early experience and 
forecast during an emergency response. JAMA 2020. doi:10.1001/
jama.2020.4031
4  Xie J, Tong Z, Guan X, Du B, Qiu H, Slutsky AS. Critical care crisis and 
some recommendations during the COVID-19 epidemic in China. 
Intensive Care Med 2020. doi:10.1007/s00134-020-05979-7 
5  Wellcome Trust. Sharing research data and findings relevant to the 
novel coronavirus (COVID-19) outbreak 2020. https://wellcome.
ac.uk/press-release/sharing-research-data-and-findings-relevant-
novel-coronavirus-covid-19-outbreak.
6  Institute of Social and Preventive Medicine. Living evidence on 
COVID-19 2020. https://ispmbern.github.io/covid-19/living-review/
index.html.
7  Xie J, Hungerford D, Chen H, et al. Development and external 
validation of a prognostic multivariable model on admission for 
hospitalized patients with COVID-19. medRxiv [Preprint] 2020. 
doi:10.1101/2020.03.28.20045997
8  DeCaprio D, Gartner J, Burgess T, et al. Building a COVID-19 
vulnerability index. arXiv e-prints [Preprint] 2020. https://ui.adsabs.
harvard.edu/abs/2020arXiv200307347D.
9  Bai X, Fang C, Zhou Y, et al. Predicting COVID-19 malignant 
progression with AI techniques. medRxiv [Preprint] 2020. 
doi:10.1101/2020.03.20.20037325
10  Feng C, Huang Z, Wang L, et al. A novel triage tool of artificial 
intelligence assisted diagnosis aid system for suspected 
covid-19 pneumonia in fever clinics. medRxiv [Preprint] 2020. 
doi:10.1101/2020.03.19.20039099
11  Jin C, Chen W, Cao Y, et al. Development and evaluation of an 
AI system for covid-19 diagnosis. medRxiv [Preprint] 2020. 
doi:10.1101/2020.03.20.20039834
12  Meng Z, Wang M, Song H, et al. Development and utilization of 
an intelligent application for aiding COVID-19 diagnosis. medRxiv 
[Preprint] 2020. doi:10.1101/2020.03.18.20035816
13  Moons KG, de Groot JA, Bouwmeester W, et al. Critical appraisal 
and data extraction for systematic reviews of prediction modelling 
studies: the CHARMS checklist. PLoS Med 2014;11:e1001744. 
doi:10.1371/journal.pmed.1001744
14  Moons KGM, Wolff RF, Riley RD, et al. PROBAST: a tool to assess risk 
of bias and applicability of prediction model studies: explanation 
and elaboration. Ann Intern Med 2019;170:W1-33. doi:10.7326/
M18-1377
15  Moons KGM, Altman DG, Reitsma JB, et al. Transparent Reporting 
of a multivariable prediction model for Individual Prognosis or 
Diagnosis (TRIPOD): explanation and elaboration. Ann Intern 
Med 2015;162:W1-73. doi:10.7326/M14-0698 
16  Steyerberg EW. Clinical prediction models: a practical approach 
to development, validation, and updating. Springer US, 2019. 
doi:10.1007/978-3-030-16399-0
17  Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for 
reporting systematic reviews and meta-analyses of studies that 
evaluate health care interventions: explanation and elaboration. 
PLoS Med 2009;6:e1000100. doi:10.1371/journal.pmed.1000100
18  Caramelo F, Ferreira N, Oliveiros B. Estimation of risk factors for 
COVID-19 mortality - preliminary results. medRxiv [Preprint] 2020. 
doi:10.1101/2020.02.24.20027268
19  Lu J, Hu S, Fan R, et al. ACP risk grade: a simple mortality index 
for patients with confirmed or suspected severe acute respiratory 
syndrome coronavirus 2 disease (COVID-19) during the early 
stage of outbreak in Wuhan, China. medRxiv [Preprint] 2020. 
doi:10.1101/2020.02.20.20025510
20  Qi X, Jiang Z, YU Q, et al. Machine learning-based CT radiomics model 
for predicting hospital stay in patients with pneumonia associated 
with SARS-CoV-2 infection: a multicenter study. medRxiv [Preprint] 
2020. doi:10.1101/2020.02.29.20029603
21  Yan L, Zhang H-T, Xiao Y, et al. Prediction of criticality in patients with 
severe Covid-19 infection using three clinical features: a machine 
learning-based prognostic model with clinical data in Wuhan. 
medRxiv [Preprint] 2020. doi:10.1101/2020.02.27.20028027
22  Yuan M, Yin W, Tao Z, Tan W, Hu Y. Association of radiologic findings 
with mortality of patients infected with 2019 novel coronavirus in 
Wuhan, China. PLoS One 2020;15:e0230548. doi:10.1371/journal.
pone.0230548
23  Song Y, Zheng S, Li L, et al. Deep learning enables accurate diagnosis 
of novel coronavirus (covid-19) with CT images. medRxiv [Preprint] 
2020. doi:10.1101/2020.02.23.20026930
24  Yu H, Shao J, Guo Y, et al. Data-driven discovery of clinical routes for 
severity detection in covid-19 pediatric cases. medRxiv [Preprint] 
2020. doi:10.1101/2020.03.09.20032219
25  Gozes O, Frid-Adar M, Greenspan H, et al. Rapid AI development cycle 
for the coronavirus (covid-19) pandemic: initial results for automated 
detection & patient monitoring using deep learning CT image 
analysis. arXiv e-prints [Preprint] 2020. https://ui.adsabs.harvard.
edu/abs/2020arXiv200305037G
26  Chen J, Wu L, Zhang J, et al. Deep learning-based model for detecting 
2019 novel coronavirus pneumonia on high-resolution computed 
tomography: a prospective study. medRxiv [Preprint] 2020. 
doi:10.1101/2020.02.25.20021568
27  Xu X, Jiang X, Ma C, et al. Deep learning system to screen coronavirus 
disease 2019 pneumonia. arXiv e-prints [Preprint] 2020. https://
ui.adsabs.harvard.edu/abs/2020arXiv200209334X
28  Shan F, Gao Y, Wang J, et al. Lung infection quantification of covid-19 
in CT images with deep learning. arXiv e-prints 2020. https://
ui.adsabs.harvard.edu/abs/2020arXiv200304655S
 o
n
 20 April 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m1328 on 7 April 2020. Downloaded from 
RESEARCH
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
29  Wang S, Kang B, Ma J, et al. A deep learning algorithm using CT 
images to screen for corona virus disease (covid-19). medRxiv 
[Preprint] 2020. doi:10.1101/2020.02.14.20023028
30  Song C-Y, Xu J, He J-Q, et al. COVID-19 early warning score: a multi-
parameter screening tool to identify highly suspected patients. 
medRxiv [Preprint] 2020. doi:10.1101/2020.03.05.20031906
31  Barstugan M, Ozkaya U, Ozturk S. Coronavirus (COVID-19) 
classification using CT images by machine learning methods. 
arXiv e-prints [Preprint] 2020. https://ui.adsabs.harvard.edu/
abs/2020arXiv200309424B
32  Gong J, Ou J, Qiu X, et al. A tool to early predict severe 2019-novel 
coronavirus pneumonia (covid-19): a multicenter study using the 
risk nomogram in Wuhan and Guangdong, China. medRxiv [Preprint] 
2020. doi:10.1101/2020.03.17.20037515
33  Jin S, Wang B, Xu H, et al. AI-assisted CT imaging analysis 
for COVID-19 screening: building and deploying a medical 
AI system in four weeks. medRxiv [Preprint] 2020. 
doi:10.1101/2020.03.19.20039354
34  Li L, Qin L, Xu Z, et al. Artificial intelligence distinguishes 
covid-19 from community acquired pneumonia on chest CT. 
Radiology 2020:200905. doi:10.1148/radiol.2020200905
35  Lopez-Rincon A, Tonda A, Mendoza-Maldonado L, et al. 
Accurate identification of SARS-CoV-2 from viral genome 
sequences using deep learning. bioRxiv [Preprint] 2020. 
doi:10.1101/2020.03.13.990242
36  Shi F, Xia L, Shan F, et al. Large-scale screening of covid-19 from 
community acquired pneumonia using infection size-aware 
classification. arXiv e-prints [Preprint] 2020. https://ui.adsabs.
harvard.edu/abs/2020arXiv200309860S
37  Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to 
severe COVID-19 and establishment of a host risk score: findings of 
487 cases outside Wuhan. Crit Care 2020;24:108. doi:10.1186/
s13054-020-2833-7
38  Zheng C, Deng X, Fu Q, et al. Deep learning-based detection for 
covid-19 from chest CT using weak label. medRxiv [Preprint] 2020. 
doi:10.1101/2020.03.12.20027185
39  ClosedLoop.ai. Covid-19 vulnerability index (CV19 index) 2020. 
https://closedloop.ai/cv19index/.
40  Chinese PLA General Hospital. Suspected covid-19 pneumonia 
diagnosis aid system 2020. https://intensivecare.shinyapps.io/
COVID19/.
41  Renmin Hospital of Wuhan University & Wuhan EndoAngel Medical 
Technology Co. AI diagnostic system for 2019-nCoV 2020. 
http://121.40.75.149/znyx-ncov/index.
42  National Supercomputing Center of Tianjin. Peunomnia CT 2020. 
https://ai.nscc-tj.cn/thai/deploy/public/pneumonia_ct.
43  Sun Yat-sen University. Discriminating covid-19 pneumonia from CT 
images 2020. http://biomed.nscc-gz.cn/server/Ncov2019.
44  Riley RD, Ensor J, Snell KIE, et al. Calculating the sample size required 
for developing a clinical prediction model. BMJ 2020;368:m441. 
doi:10.1136/bmj.m441
45  Van Calster B, McLernon DJ, van Smeden M, Wynants L, Steyerberg 
EW, Topic Group ‘Evaluating diagnostic tests and prediction models’ 
of the STRATOS initiative. Calibration: the Achilles heel of predictive 
analytics. BMC Med 2019;17:230. doi:10.1186/s12916-019-
1466-7 
46  Steyerberg EW. Clinical prediction models: a practical approach 
to development, validation, and updating. Springer US, 2009. 
doi:10.1007/978-0-387-77244-8
47  Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data 
in the presence of competing risks. Circulation 2016;133:601-9. 
doi:10.1161/CIRCULATIONAHA.115.017719
48  Riley RD, Ensor J, Snell KI, et al. External validation of clinical 
prediction models using big datasets from e-health records or 
IPD meta-analysis: opportunities and challenges [correction: BMJ 
2019;365:l4379]. BMJ 2016;353:i3140. doi:10.1136/bmj.i3140
49  Debray TP, Riley RD, Rovers MM, Reitsma JB, Moons KG, Cochrane IPD 
Meta-analysis Methods group. Individual participant data (IPD) meta-
analyses of diagnostic and prognostic modeling studies: guidance 
on their use. PLoS Med 2015;12:e1001886. doi:10.1371/journal.
pmed.1001886
50  Steyerberg EW, Harrell FEJr. Prediction models need appropriate 
internal, internal-external, and external validation. J Clin 
Epidemiol 2016;69:245-7. doi:10.1016/j.jclinepi.2015.04.005
51  Wynants L, Kent DM, Timmerman D, Lundquist CM, Van Calster B. 
Untapped potential of multicenter studies: a review of cardiovascular 
risk prediction models revealed inappropriate analyses and wide 
variation in reporting. Diagn Progn Res 2019;3:6. doi:10.1186/
s41512-019-0046-9
52  Wynants L, Riley RD, Timmerman D, Van Calster B. Random-effects 
meta-analysis of the clinical utility of tests and prediction models. 
Stat Med 2018;37:2034-52. doi:10.1002/sim.7653
53  Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality 
of adult inpatients with COVID-19 in Wuhan, China: a retrospective 
cohort study. Lancet 2020;395:1054-62. doi:10.1016/S0140-
6736(20)30566-3
54  Li K, Wu J, Wu F, et al. The clinical and chest CT features associated 
with severe and critical covid-19 pneumonia. Invest Radiol 2020. 
doi:10.1097/RLI.0000000000000672
55  Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular 
metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020. 
doi:10.1007/s00392-020-01626-9
56  Jain V, Yuan J-M. Systematic review and meta-analysis of predictive 
symptoms and comorbidities for severe COVID-19 infection. medRxiv 
[Preprint] 2020. doi:10.1101/2020.03.15.20035360
57  Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et 
al, Latin American Network of Coronavirus Disease 2019-COVID-19 
Research (LANCOVID-19). Electronic address: https://www.
lancovid.org. Clinical, laboratory and imaging features of COVID-19: 
A systematic review and meta-analysis. Travel Med Infect 
Dis 2020:101623. doi:10.1016/j.tmaid.2020.101623
58  Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated 
with severe coronavirus disease 2019 (COVID-19) infections: a 
meta-analysis. Clin Chim Acta 2020;506:145-8. doi:10.1016/j.
cca.2020.03.022
59  Zhao X, Zhang B, Li P, et al. Incidence, clinical characteristics 
and prognostic factor of patients with covid-19: a systematic 
review and meta-analysis. medRxiv [Preprint] 2020. 
doi:10.1101/2020.03.17.20037572
60  Johansson MA, Saderi D. Open peer-review platform for COVID-19 
preprints. Nature 2020;579:29. doi:10.1038/d41586-020-00613-4 
61  Xu B, Kraemer MU, Gutierrez B, et al. Open access epidemiological 
data from the COVID-19 outbreak. Lancet Infect Dis 2020. 
doi:10.1016/s1473-3099(20)30119-5
62  Società Italiana di Radiologia Medica e Interventistica. COVID-19 
database 2020. https://www.sirm.org/category/senza-categoria/
covid-19/.
63  Kaggle. COVID-19 Kaggle community contributions 2020. https://
www.kaggle.com/covid-19-contributions.
64  Cohen JP, Morrison P, Dao L. COVID-19 image data collection. arXiv 
[Preprint] 2020. doi:2003.11597, https://github.com/ieee8023/
covid-chestxray-dataset.
65  Dutch CardioVascular Alliance. European registry of patients with 
covid-19 including cardiovascular risk and complications 2020. 
https://capacity-covid.eu/.
66  World Health Organization. Coronavirus disease (COVID-19) technical 
guidance: early investigations protocols 2020. https://www.who.int/
emergencies/diseases/novel-coronavirus-2019/technical-guidance/
early-investigations.
67  Infervision. Infervision launches hashtag#AI-based 
hashtag#Covid-19 solution in Europe 2020. https://www.
linkedin.com/posts/infervision_ai-covid-medicine-activity-
6650772755031613440-TqLJ.
68  Surgisphere Corporation. COVID-19 response center 2020. https://
surgisphere.com/covid-19-response-center/.
69  Enfield K, Miller R, Rice T, et al. Limited utility of SOFA and 
APACHE II prediction models for ICU triage in pandemic Influenza. 
Chest 2011;140:913A. doi:10.1378/chest.1118087
70  Van Calster B, Vickers AJ. Calibration of risk prediction models: impact 
on decision-analytic performance. Med Decis Making 2015;35:162-
9. doi:10.1177/0272989X14547233 
71  van Smeden M, Moons KG, de Groot JA, et al. Sample size 
for binary logistic prediction models: beyond events per 
variable criteria. Stat Methods Med Res 2019;28:2455-74. 
doi:10.1177/0962280218784726 
Web appendix: Supplementary material
 o
n
 20 April 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m1328 on 7 April 2020. Downloaded from 
